Let's transform UTERINE HEALTH
together!
Every woman faces uterine disorders throughout her lifetime: excessive bleeding, chronic pain, infertility...
Yet, the only solutions they are offered are either invasive surgery or high-dose hormonal treatments that cause debilitating side effects.
At Womed, we develop intrauterine therapies to relieve women from the burden of infertility, bleeding and endometriosis while respecting the integrity of their body.
To make our solutions available to as many people as possible and as quickly as possible, Womed is now entering a new key phase of funding. Because those issues affect all women, we are opening up Womed’s equity to anyone who wishes to make a concrete commitment to our cause.
Join the movement now
To invest in Womed and become a shareholder, follow the link to our recommended plaform based on your profile:
Lita est la plateforme pionnière de l’investissement dans les entreprises à impact écologique et social
.png){kind=logo}
Capital Cell is the leading platform to invest in European life science companies
Investing in unlisted companies carries a significant risk of partial or total loss of the amounts invested, as well as a risk of illiquidity.
How do we deliver gentle and precise care?
Our foundational technology, a patented tri-block copolymer, has been developed for several years at the University of Montpellier.
Its unique properties allow for easy insertion through the cervix and tunable degradability. It can also deliver low-doses of drugs right inside the uterus where it is needed.
We are leveraging this platform into a powerful pipeline of 4 products targeting intrauterine adhesions, fibroids, acute bleeding, and endometriosis.
How will your contribution boost our development?
1
Global Commercialization of Womed Leaf
Accelerate the international rollout to make our FDA-approved, first-in-class adhesion barrier accessible to every woman recovering from uterine surgery.
2
Phase II Clinical Study of Eynia
Fund the phase II clinical study for our game-changing fibroid treatment, to bring a non-surgical, non-systemic solution to market.
3
Pipeline Acceleration for Acute Bleeding & Endometriosis
Drive the development of our next-generation therapies to tackle two of the most debilitating and underserved female health conditions.